Uncovering the inflammatory axis: Clinical relevance of Irisin and Myeloperoxidase in adolescent bronchial asthma

Abstract

Bronchial asthma is a chronic inflammatory disease with airway blockage, hyper-responsiveness. Key biomarkers like irisin, myeloperoxidase (MPO), and glucose regulate inflammation and metabolic dysfunction. Irisin is a novel parameter for adolescents asthma. In this study assessed  prognostic significance of irisin and MPO in predicting asthma outcomes. A case-control study based on prevalence (2.2%) of asthma in adolescents, involving 70 adolescents after excluding 30 samples from 100 participants (due to presence of infections), categorized  to 35 patients with bronchial asthma and 35 age and BMI matched of apparently healthy controls. The study categorized patients into 35 with bronchial asthma and 35 healthy controls. The patients were further divided into 20 with allergic bronchial asthma (P.ABA) and 15 with non-allergic bronchial asthma (P.NABA), techniques were used ELISA (irisin, MPO) , AFIAS (IgE), and  Auto Analyzer (glucose). Our results of Irisin, myeloperoxidase, and glucose levels were significantly p<0.05 elevated in P.ABA and P.NABA patients compared to controls. The study found significant positive correlations among all parameters, with over 80% of the AUC for irisin and myeloperoxidase based on ROC curve. These findings highlight importance of monitoring irisin, MPO, IgE, and glucose levels in bronchial asthma patients to better understand and predict long-term outcomes.